Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904743 · ClinicalTrials.gov registry record · Phase 4
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
A Phase 4 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 141
- Enrollment target
NCT05904743: Completed Phase 4 study, sponsored by Mannkind Corporation.
NCT05904743 is a Phase 4 study that has completed, run by Mannkind Corporation. The registered enrollment target is 141 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05904743, a Phase 4 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 141 participants
- Enrollment target
Study Summary
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen of insulin degludec plus inhaled insulin (Afrezza) and CGM or continuation of usual care. The primary outcome of the RCT is at 17 weeks. The RCT will be followed by a 13-week extension phase in which participants in both groups will use the degludec-inhaled insulin regimen.
Primary Outcome
Change in HbA1c from baseline to 17 weeks (non-inferiority margin 0.4%)
Interventions
- BIOLOGICAL Afrezza
- BIOLOGICAL Rapid-acting Insulin Analog
- BIOLOGICAL Basal Insulin
- BIOLOGICAL insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 4 |
What the finished NCT05904743 record still lists
NCT05904743 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 4 interventions - of which Afrezza is the first listed.
NCT05904743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05904743 about?
NCT05904743 is a clinical study titled "INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes". INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to ...
What is the current status of trial NCT05904743?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 141 participants. The study started on 2023-07-07. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05904743?
The interventions under investigation include: Afrezza (BIOLOGICAL), Rapid-acting Insulin Analog (BIOLOGICAL), Basal Insulin (BIOLOGICAL), insulin degludec (BIOLOGICAL).
Who is sponsoring clinical trial NCT05904743?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05904743's enrollment target sits among peer trials
141 580th of 2000 higher than 1,420 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI